<a href=Medtronic” width=”290″ height=”150″ align=”left” />

US-based medical technology provider Medtronic has received a Health Canada licence for its deep brain stimulation (DBS) therapy for treating patients with refractory epilepsy.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

DBS therapy uses a surgically implanted medical device, similar to a cardiac pacemaker, to deliver mild electrical pulses to precisely targeted areas of the brain.

The Health Canada licence was based on data from the Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy (SANTE) clinical trial.

In the prospective randomised double-blind pivotal SANTE trial, 110 patients were implanted with Medtronic’s DBS system at 17 centres in the US, to assess the use of DBS therapy for patients with medically refractory epilepsy with partial-onset seizures.

Medtronic’s RestoreSensor neurostimulator with AdaptiveStim technology is designed to sense a change in the patient’s body position or activity and automatically adjust stimulation to deliver the right amount of pain relief.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Activa line of neurostimulators, such as the Activa Primary Cell, Activa Single Channel and Activa Rechargeable Cell provides clinicians with the ability to deliver stimulation in constant voltage or constant current mode, enabling physicians with a choice based on their preference and clinical needs.

DBS therapy is currently licensed in Canada and the European Union for the treatment of the disabling symptoms of essential tremors, advanced Parkinson’s disease and dystonia, for which it is under a humanitarian device exemption (HDE) in the US.

The company’s Neuromodulation business includes neurostimulation and implantable, targeted drug delivery systems for the management of chronic pain, common movement disorders, spasticity and urologic and gastrointestinal disorders.

Image: Medtronic World Headquarters, Fridley, Minnesota, US. Photo: Bobak Ha’Eri.